AU2012353330B2 - Chimeric double-stranded nucleic acid - Google Patents

Chimeric double-stranded nucleic acid Download PDF

Info

Publication number
AU2012353330B2
AU2012353330B2 AU2012353330A AU2012353330A AU2012353330B2 AU 2012353330 B2 AU2012353330 B2 AU 2012353330B2 AU 2012353330 A AU2012353330 A AU 2012353330A AU 2012353330 A AU2012353330 A AU 2012353330A AU 2012353330 B2 AU2012353330 B2 AU 2012353330B2
Authority
AU
Australia
Prior art keywords
modified
nucleic acid
base
rna
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012353330A
Other languages
English (en)
Other versions
AU2012353330A1 (en
Inventor
Hidehiro Mizusawa
Kazutaka Nishina
Satoshi Obika
Takanori Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Medical and Dental University NUC
Original Assignee
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Medical and Dental University NUC filed Critical Tokyo Medical and Dental University NUC
Publication of AU2012353330A1 publication Critical patent/AU2012353330A1/en
Application granted granted Critical
Publication of AU2012353330B2 publication Critical patent/AU2012353330B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2012353330A 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid Active AU2012353330B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-275488 2011-12-16
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Publications (2)

Publication Number Publication Date
AU2012353330A1 AU2012353330A1 (en) 2014-07-31
AU2012353330B2 true AU2012353330B2 (en) 2018-04-19

Family

ID=47559626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012353330A Active AU2012353330B2 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid

Country Status (9)

Country Link
US (6) US9816089B2 (cg-RX-API-DMAC7.html)
EP (1) EP2791335B1 (cg-RX-API-DMAC7.html)
JP (7) JP6112569B2 (cg-RX-API-DMAC7.html)
CN (2) CN112386605A (cg-RX-API-DMAC7.html)
AU (1) AU2012353330B2 (cg-RX-API-DMAC7.html)
CA (2) CA3106312C (cg-RX-API-DMAC7.html)
ES (1) ES2707232T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04590A (cg-RX-API-DMAC7.html)
WO (1) WO2013089283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
CA3106312C (en) * 2011-12-16 2025-09-23 National University Corporation Tokyo Medical And Dental University CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CA2901983A1 (en) * 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
JP6300212B2 (ja) * 2013-03-21 2018-03-28 国立大学法人 東京医科歯科大学 二重鎖核酸結合剤、当該結合剤−二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
US10190117B2 (en) * 2013-06-16 2019-01-29 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
JP6482475B2 (ja) * 2014-01-07 2019-03-13 レナセラピューティクス株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
EP3353306A4 (en) 2015-09-25 2019-06-05 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3366773A4 (en) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. NUCLEIC COMPLEX
WO2017068791A1 (ja) * 2015-10-23 2017-04-27 レナセラピューティクス株式会社 少なくとも１つのバルジ構造を有する核酸複合体
WO2017094745A1 (ja) * 2015-12-01 2017-06-08 国立大学法人大阪大学 核酸を含む経腸投与用組成物
CN116064544A (zh) * 2016-01-26 2023-05-05 日产化学株式会社 单链寡核苷酸
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3517610A4 (en) * 2016-09-23 2020-05-27 National University Corporation Tokyo Medical and Dental University Blood-brain barrier permeable heteroduplex nucleic acid
JP7129702B2 (ja) 2016-09-29 2022-09-02 国立大学法人 東京医科歯科大学 オーバーハングを有する二本鎖核酸複合体
MX2019009305A (es) 2017-02-06 2019-09-19 Nissan Chemical Corp Oligonucleotido de cadena simple.
US11638717B2 (en) 2017-03-29 2023-05-02 Shionogi & Co., Ltd. Complex of nucleic acid medicine and multibranched lipid
EP3604531A4 (en) * 2017-03-31 2020-12-23 Aichi Medical University NUCLEIC ACID ANTISENS FOR INHIBITION OF CHONDROITIN SULPHATE BIOSYNTHESIS
JP6974872B2 (ja) * 2017-06-30 2021-12-01 国立大学法人 東京医科歯科大学 ヘテロ二本鎖型ａｎｔｉｍｉＲ
US11555188B2 (en) 2017-07-26 2023-01-17 Nissan Chemical Corporation Single-stranded oligonucleotide
EP4257691A3 (en) 2017-12-14 2024-01-10 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3760209B1 (en) 2018-02-28 2023-11-22 National University Corporation Tokyo Medical and Dental University Ischemic-lesion-site-specific gene therapy
WO2019181946A1 (ja) * 2018-03-19 2019-09-26 国立大学法人東京医科歯科大学 毒性が軽減した核酸
WO2019182294A1 (ko) * 2018-03-19 2019-09-26 주식회사 케이티 비디오 신호 처리 방법 및 장치
CA3094303A1 (en) 2018-03-20 2019-09-26 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity
JP7262816B2 (ja) * 2018-03-22 2023-04-24 国立大学法人 東京医科歯科大学 ヘテロ核酸のｂｂｂ通過脂質リガンド
JP2022523467A (ja) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ 動的な薬物動態を修飾するアンカー
JP7687682B2 (ja) * 2019-04-08 2025-06-03 国立大学法人東京科学大学 筋疾患治療用医薬組成物
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
CN115103911A (zh) * 2019-10-11 2022-09-23 国立大学法人东京医科齿科大学 修饰的异源核酸
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
EP4098747A4 (en) 2020-01-31 2025-03-26 Sanwa Kagaku Kenkyusho Co., Ltd. ATN1 ANTISENSE OLIGONUCLEOTIDE
JPWO2021177418A1 (cg-RX-API-DMAC7.html) 2020-03-04 2021-09-10
EP4123023A4 (en) * 2020-03-16 2024-07-17 National University Corporation Tokyo Medical and Dental University Heteronucleic acid containing morpholino nucleic acid
JP7751302B2 (ja) 2020-06-15 2025-10-08 リードファーマ株式会社 架橋型ヌクレオシドおよびヌクレオチド
US20240002853A1 (en) 2020-11-23 2024-01-04 Alpha Anomeric Sas Nucleic acid duplexes
WO2022183102A1 (en) * 2021-02-26 2022-09-01 Northwestern University Cell-free biosensors with dna strand displacement circuits
US20240240183A1 (en) * 2021-05-25 2024-07-18 National University Corporation Tokyo Medical And Dental University Heteronucleic acid containing scpBNA or AmNA
BR112023024384A2 (pt) 2021-05-31 2024-02-15 Rena Therapeutics Inc Complexo de ácido nucleico ligado ao ligante
US20250339459A1 (en) * 2021-08-19 2025-11-06 National University Corporation Tokyo Medical And Dental University Modified heteronucleic acid containing morpholino nucleic acid
EP4389893A4 (en) 2021-08-21 2025-09-10 Takeda Pharmaceuticals Co PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
JPWO2023042876A1 (cg-RX-API-DMAC7.html) * 2021-09-15 2023-03-23
WO2023064937A1 (en) * 2021-10-14 2023-04-20 Arizona Board Of Regents On Behalf Of Arizona State University Programmable delivery platforms for rna structures
EP4428238A1 (en) 2021-11-02 2024-09-11 Rena Therapeutics Inc. Ligand-bound nucleic acid complex
WO2023105898A1 (ja) * 2021-12-07 2023-06-15 リードファーマ株式会社 アンチセンスオリゴヌクレオチド複合体
EP4596694A1 (en) 2022-09-29 2025-08-06 Institute Of Science Tokyo Nucleic acid molecule containing 5'-cyclopropylene modification
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024228398A1 (ja) * 2023-05-02 2024-11-07 国立大学法人東京医科歯科大学 グアニン四重鎖構造を誘導するための核酸剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2253639A1 (en) 1997-09-12 2010-11-24 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2002249967A1 (en) 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
AU2003247521A1 (en) * 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
WO2004044181A2 (en) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
EA009670B1 (ru) * 2003-09-18 2008-02-28 Ай Эс Ай Эс ФАРМАСЬЮТИКАЛЗ, ИНК. МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2011204898A1 (en) * 2004-04-09 2011-08-11 Biodelivery Sciences International, Inc Nucleotide-cochleate compositions and methods of use
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
US20090292006A1 (en) 2006-05-05 2009-11-26 Sanjay Bhanot Compounds and methods for modulating expression of dgat2
CA2660438A1 (en) * 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
JP2010505432A (ja) 2006-10-09 2010-02-25 サンタリス ファーマ アー／エス Ｐｃｓｋ９を調節するためのｒｎａアンタゴニスト化合物
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
EP2134736A4 (en) * 2007-03-15 2013-05-29 Jyoti Chattopadhyaya FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
NZ587178A (en) * 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2133425A1 (en) 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
EP2488210A4 (en) * 2009-10-12 2014-04-30 Smith Holdings Llc METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
CA3106312C (en) * 2011-12-16 2025-09-23 National University Corporation Tokyo Medical And Dental University CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
CN105264073A (zh) * 2013-05-30 2016-01-20 国立大学法人东京医科齿科大学 用于递送治疗性寡核苷酸的双链剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEKERLE V ET AL, "Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, (2005), vol. 8, no. 3, pages 516 - 527 *

Also Published As

Publication number Publication date
EP2791335B1 (en) 2018-11-14
US20180073024A1 (en) 2018-03-15
JP2017140031A (ja) 2017-08-17
JP6638923B2 (ja) 2020-02-05
CN112386605A (zh) 2021-02-23
CN104126010A (zh) 2014-10-29
US12344841B2 (en) 2025-07-01
CA2859581C (en) 2022-03-22
ES2707232T3 (es) 2019-04-03
JP7174384B2 (ja) 2022-11-17
US20180320181A1 (en) 2018-11-08
WO2013089283A1 (en) 2013-06-20
US20190270996A1 (en) 2019-09-05
CA3106312A1 (en) 2013-06-20
CA3106312C (en) 2025-09-23
IN2014CN04590A (cg-RX-API-DMAC7.html) 2015-09-18
AU2012353330A1 (en) 2014-07-31
JP7423015B2 (ja) 2024-01-29
JP2020039364A (ja) 2020-03-19
US11034955B2 (en) 2021-06-15
US20240158790A1 (en) 2024-05-16
CA2859581A1 (en) 2013-06-20
JP2015502134A (ja) 2015-01-22
JP6416301B2 (ja) 2018-10-31
JP6112569B2 (ja) 2017-04-12
US20140302603A1 (en) 2014-10-09
JP2022000426A (ja) 2022-01-04
JP2018203779A (ja) 2018-12-27
JP6960123B2 (ja) 2021-11-05
JP2022171811A (ja) 2022-11-11
US20210340540A1 (en) 2021-11-04
US10337006B2 (en) 2019-07-02
US9816089B2 (en) 2017-11-14
JP2021011501A (ja) 2021-02-04
US10329567B2 (en) 2019-06-25
EP2791335A1 (en) 2014-10-22
CN104126010B (zh) 2021-04-06

Similar Documents

Publication Publication Date Title
AU2012353330B2 (en) Chimeric double-stranded nucleic acid
US10526602B2 (en) Segmented micro RNA mimetics
EP2898887B1 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
CN105008533A (zh) 嵌合单链反义多核苷酸和双链反义试剂
WO2023011360A1 (zh) 一种增强核酸药物缓释能力的方法
EP3256586B1 (en) Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
RU2822093C1 (ru) Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)